Vascularization of melanoma by mobilization and remodeling of preexisting latent vessels to patency

Cancer Research

Volumn 65, Issue 3, 2005, Pages 913-918

  Lu, Weixin ^a   Schroit, Alan Jay ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) NITROARGININE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ERYTHROCYTE; FEMALE; FLUORESCENCE; IMAGING; MELANOMA; MOBILIZATION; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR PATENCY; VASCULARIZATION;

ANIMALS; CELL GROWTH PROCESSES; ENDOTHELIAL CELLS; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITROARGININE; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 13444252266     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
3. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
4. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356-62.
5. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
6. Kusters B, Leenders WP, Wesseling P, et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002;62:341-5.
7. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002;3:53-7.
8. Krogh A. A Contribution to the physiology of the capillaries. Noble Lecture. 1920 [cited 1920 Dec 11];1-8. Available from: http://www.nobel.se/ medicine/lau-reates/1920/krogh-lecture.html.
9. Granger HJ, Goodman AH, Cook BH. Metabolic models of microcirculatory regulation. Fed Proc 1975;34:2025-30.
10. Wu HM, Yuan Y, McCarthy M, Granger HJ. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism. Am J Physiol 1996;271:H1087-93.
11. Anderson DR, Davis EB. Glaucoma, capillaries and pericytes. Preliminary evidence that carbon dioxide relaxes pericyte contractile tone. Ophthal 1996;210:280-4.
12. Pallone TL, Zhang Z, Rhinehart K. Physiology of the renal medullary microcirculation. Am J Physiol 2003;284:F253-66.
13. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132.
14. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000;80:99-115.
15. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002;196:1497-506.
16. Talmadge JE, Fidler IJ. Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J Natl Cancer Inst 1982;69:975-80.
17. Dvorak HF, Orenstein NS, Carvalho AC, et al. Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 1979;122:166-74.
18. Cahlin C, Gelin J, Delbro D, Lonnroth C, Doi C, Lundholm K. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 2000;60:1742-9.
19. Udagawa T, Fernandez A, Achilles EG, Folkman J, D'Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002;16:1361-70.
20. Ribatti D, Vacca A, Dammacco F. New non-angiogenesis dependent pathways for tumour growth. Eur J Cancer 2003;39:1835-41.
21. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747-57.
22. Tozer GM, Everett SA. Nitric oxide in tumour biology and cancer therapy. Part 1: physiological aspects. Clin Oncol (R Coll Radiol) 1997;9:282-93.
23. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
24. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992;107:1092-5.
25. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-32.
26. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991;174:1275-8.
27. Dafni H, Landsman L, Schechter B, Kohen F, Neeman M. MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper-permeability and lymphatic uptake, followed by rapid inactivation of the growth factor. NMR Biomed 2002;15:120-31.